MDACC Study No:2011-0448 ( NCT No: NCT01286753)
Title:An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor Vemurafenib in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine
Principal Investigator:Maria E. Cabanillas
Treatment Agent:RO5185426
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if vemurafenib can help to
control papillary thyroid cancer. Researchers will also be studying the drug's
effect on biomarkers (proteins in the blood/tissue that may be related to your
reaction to the study drug). The safety and possible side effects of this drug
will also be studied.

Vemurafenib is designed to block the BRAF gene mutation. This mutation causes
cancer and cancer growth. By blocking this mutation, the drug may kill the
cancer cells with the mutation and/or stop the tumor from growing.
Hide details for General InformationGeneral Information

Disease Group:Thyroid
Phase of Study:Phase II
Treatment Agents:RO5185426
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:F. Hoffman-LaRoche
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Maria E. Cabanillas
For Clinical Trial Enrollment:713-563-0764
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults